In exploratory analyses of 22 ICI-treated patients, PD-L1 ≥ 50% showed higher response rates (64% vs. 9%) and longer time to treatment failure (3.4 vs. 1.4 months).<h4>Conclusions</h4>High PD-L1 expression in EGFRm NSCLC is associated with more aggressive morphologic features and modifies the association between post-progression ICI and survival. This evidence concerns the gene CD274 and non-small cell lung carcinoma.